Vertex (NASDAQ:VRTX) Owns HCV Treatment with TVR

With a strong pipeline and TVR being the top drug for HCV treatment through 2012, Vertex (NASDAQ:VRTX) looks good for the short and long term.

Brean says, "We consider TVR to be the best in class drug for HCV treatment, and to remain so until 2012. Additionally, VRTX has pipeline drugs for RA, CF and epilepsy, but our valuation is driven by a discounted cash flow analysis and a disounted multiples analysis that only incorporates projected TVR and VX-222 revenue, in an effort to be more conservative."

Brean Murray Carret & Co. launched coverage on Vertex (VRTX) with a "Buy" rating. Vertex closed Friday at $39.01, down $0.38, or 0.96 percent. Brean has a price target of $50 on Vertex.